SIMCERE PHARMA's stock soared 7.87% during the morning trading session on Friday, reflecting strong investor confidence in the company's strategic direction.

The surge follows the company's announcement that Zhou Yunshu, the former Chairman of HENGRUI PHARMA, has officially joined SIMCERE PHARMA as Chief Executive Officer. The company highlighted Zhou's extensive experience in managing domestic pharmaceutical enterprises and his proven track record at HENGRUI PHARMA, where he successfully drove the transition toward innovative drug development.

Investors were also encouraged by SIMCERE PHARMA's recently released annual results, which showed robust growth. Total revenue increased by 16.5% year-on-year to RMB 7.731 billion, with innovative drug revenue surging 27.9% to account for a record 81.5% of total revenue. Net profit attributable to shareholders jumped 86.2%. With ten innovative drugs already on the market and more than five additional candidates nearing approval for launch between 2026 and 2028, the company has laid a solid foundation for sustained future growth.